Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

NCT06771115 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

176

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity

Interventions

DRUG: VTX3232 Dose A
DRUG: Placebo
DRUG: VTX3232 Dose A in combination with semaglutide
DRUG: Placebo in combination with semaglutide

Sponsor

Zomagen Biosciences Ltd.